Big Pharma has lost billions of dollars recently, with plant closures and layoffs totaling 40,000 jobs so far and climbing. But the cuts in most Big Pharma companies are likely to be more, not less, as a prescription drug rehab programs necessary to lead the future.

While some companies are not always going to lower-pharmaceutical interests, other closing plants and reducing labor costs and boost sagging profits. For Big Pharma, like allState-owned enterprises, is the nuts and bolts on the bottom line. Being in the improvement of the health business is not a factor in the numbers game, nor is it of concern that millions of people in drug rehab programs, or should be, because their products.

An article in the Guardian Unlimited, says that the Swiss drug maker Novartis AG, a layoff of 2,500 employees announced belongs – on a number of cut-backs in the Big Pharma is spreading landscape. Last WeekSanofi-Aventis announced in France, spending cuts, and Bristol-Myers Squibb has said it will cut 10% of workers and close several factories. Most other large pharmaceutical companies are already taking steps to prevent business losses, including Eli Lilly, Johnson & Johnson, AstraZeneca, Pfizer, GlaxoSmithKline, Merck, Schering-Plow and Amgen – many of them names that drug rehab consultant, not only stock market investors are familiar.

Among the problems that big pharma facesresearch divisions of production are too few new branded drugs, with patents on many profitable brands will soon expire. Cheaper generic drugs will replace the brand, and these gains will not go into the pockets of Big Pharma. It will sell no fewer drugs, but they are more affordable. As for drugs, we will see even more dependencies and requirements for drug rehab services.

Big Pharma has allocated billions of dollars for drugs that have been "black lostBox "warnings on the labels of the FDA and more billions of $ for drugs withdrawn from the market because they have the deadly risks. As a result, more people than ever began to distrust big pharmaceutical products and prevention of prescription medicines to be even remotely similar to the known dangerous drugs.

For example, Merck pulled its arthritis painkiller Vioxx from the market in 2004 because of serious cardiovascular side effects. The withdrawal of Merck costs 2.5 billion U.S. dollars per year. Most of theFormer Vioxx users were expected to move to arthritis drug Celebrex from Pfizer – similar to Vioxx, but also with a black-box warning. Instead, half of them on Celebrex, along with all other similar provisions. Not only that Pfizer does not pick up business Vioxx, Celebrex, but 60% of his customers went away, because for safety. Pfizer's profit on Celebrex, probably 4 billion U.S. dollars per year, dropped to $ 2 billion.

In the meantime, a new generation of drugs with unknownCause side effects or problems, dependence on drug rehab could be the development of biotech companies that are not big pharma players. They expect to be bought or acquired, as a rule, because these drugs had a market threat to big pharmaceutical companies represented, and Big Pharma's marketing infrastructure already exists. Such acquisitions are usually delayed until some testing shows that it is not something clear, safe and additions, the drugs also known for drug rehabCenters.

So the need for drug rehab is sure, despite the increase in the cut-backs in Big Pharma. With millions of people already dependent on prescription drugs and require drug detox and drug rehab now, and can come with cheaper drugs, we expect an even greater need for drug rehab program facilities for the next few years to see.